Signet Therapeutics, Backed by XtalPi, Advances World’s First Organoid and AI-Developed Targeted Therapy for Diffuse Gastric Cancer into Clinical Trials

Jun 26, 2024 18:29 CST Updated 18:29

SIGNET

Innovative Targeted Cancer Drug Developer

June 26,SIGNETAnnounced that its self-developedThe World's First Targeted Drug for the Treatment of Diffuse Gastric CancerPipeline Receives FDA IND Clearance Ahead of Schedule.

This targeted drug is alsoThe World's First Class 1 Innovative Targeted Drug Developed by Integrating Organoid Disease Models with AIIn drug discovery and design, Signet Therapeutics has deeply collaborated with XtalPi (2228.HK), a leading AI-driven pharmaceutical company, targeting innovative targets discovered by Signet, using onlyMore than 6 monthsDesigned and optimized a candidate compound with a novel molecular structure and superior comprehensive drug-like properties; in the efficacy evaluation, SIGNET utilized its established...Organoid Platform Based on Patient Genomic Characteristics, which can better screen out molecules that are closer to the real responses of patients, thereby increasing the potential for successful clinical trials.

From the discovery of a new target to the approval of IND, Signet Therapeutics took just over three years., verifying the superiority of its drug development model based on organoid disease models + AI.

In addition to diffuse gastric cancer, the preclinical efficacy also characterizes this targeted drug inMalignant metastatic cancers such as ovarian cancer, triple-negative breast cancer, and pancreatic cancerIt has demonstrated superior efficacy as a single agent in China, as well as showing excellent therapeutic effects when combined with chemotherapy or targeted drugs for KRAS and EGFR mutations. As clinical research progresses, it is expected to play a role in more treatment areas.

SIGNET Therapeutics Officially Enters Clinical Stage and Will Launch Phase I Clinical Trials. It Aims to Fill the Global Market Gap for Effective Drugs in Diffuse Gastric Cancer, Bringing Benefits to Patients as Soon as Possible. It Also Looks Forward to Empowering More Innovative Pharmaceutical Companies with the New Drug Development Model Combining Organoid Disease Models and AI, Continuously Accelerating the De Novo Discovery and Clinical Translation of Drugs, and Bringing More High-Quality and Efficient Drugs to Patients.

SIGNET isThe First Cancer Innovative Targeted Drug R&D Company in China Based on Organoid Disease Models + AIIt was originally founded at Harvard, landed in Shenzhen in 2020, and completed an angel round of financing of nearly 150 million yuan within a year, with investors includingTianTu Investment, FiveSource Capital, XtalPi, YunJiu CapitalThisetc.

The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and novel target discovery. By integrating AI-driven screening, synthesis, and optimization of small-molecule compounds, the company develops first-in-class innovative targeted drugs. Currently, the company hasThree Drug PipelinesThe first pipeline has entered the clinical stage. The company owns a 1200㎡ R&D site and a 500㎡ experimental animal facility.

SIGNETThe disease model platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development, contributing to the birth of more innovative drugs.

—The End—

Recommended Reading